Although poly ADP-ribose polymerase (PARP) inhibitors are not new to the market, two of them recently gained approval for use in prostate cancer for the first time. The therapies will bring a new option for the treatment of certain subpopulations of patients.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.